Gudrun Stengel

Gudrun Stengel is the CEO and co-founder of Alida Biosciences. Gudrun has over 10 years of experience in the biotech industry, with a focus on product development.

Stengel began their career as a research scientist at CU Boulder, where they worked on developing new methods for DNA sequencing. Gudrun then joined Affymetrix as a Scientist II, working on developing new microarray technologies. In 2013, they moved to Sequenom as a Scientist II, where they worked on developing new products for the company.

In 2014, Stengel joined Illumina as a Staff Scientist. Gudrun led the product development team responsible for consumables and reagents for major Illumina platforms. During their time at Illumina, they launched the high density flowcell for HSX and led the development of onboard clustering for NovaSeq6000 and NovaSeq Xp.

In 2018, Stengel left Illumina to join Encodia as the Director of Product Development. At Encodia, they were responsible for leading the reagent and sample prep development for a new next-gen proteomics technology. Gudrun was also a core team lead for a key company project.

In 2020, Stengel left Encodia to join Element Biosciences as the Director of Assay and Reagent Development.

Gudrun Stengel has a Ph.D. in Biophysical Chemistry from the Ph.D. Max Planck Institute, an EPSE from UC San Diego, and a B. Sc. and M.Sc. in Chemistry from Justus Liebig University Giessen.